Department of Medical Oncology, Xiang'an Hospital of Xiamen University, Xiamen, China.
Department of Medical Oncology, Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, Xiamen, China.
Front Immunol. 2022 Aug 18;13:968777. doi: 10.3389/fimmu.2022.968777. eCollection 2022.
The SCF (Skp1-cullin-F-box proteins) complex is the largest family of E3 ubiquitin ligases that mediate multiple specific substrate proteins degradation. Two ring-finger family members RBX1/ROC1 and RBX2/RNF7/SAG are small molecular proteins necessary for ubiquitin ligation activity of the multimeric SCF complex. Accumulating evidence indicated the involvement of RBX proteins in the pathogenesis and development of cancers, but no research using pan-cancer analysis for evaluating their difference has been directed previously.
We investigated RBX1/2 expression patterns and the association with clinicopathological features, and survivals of cancer patients obtained from the TCGA pan-cancer data. The binding energies of RBX1/2-CUL1 complexes were preliminarily calculated by using molecular dynamics simulations. Meanwhile, we assessed their immune infiltration level across numerous databases, including TISIDB and Timer database.
High expression levels of RBX1/2 were observed in most cancer types and correlated with poor prognosis of patients analyzed. Nonetheless, exceptions were observed: RBX2 expression in KICH was higher than normal renal tissues and played a detrimental role in KICH. The expression of RBX1 was not associated with the prognostic risk of KICH. Moreover, the combination of RBX1 and CUL1 expression is more stable than that of RBX2 and CUL1. RBX1/2 expression showed their own specific characteristics in tumor pathological stages and grades, copy number variation and immune components.
These findings not only indicated that the difference of RBX1/2 might result in varying degrees of tumor progression, but also suggested that they might serve as biomarkers for immune infiltration in cancers, shedding new light on therapeutics of cancers.
SCF(Skp1-cullin-F-box 蛋白)复合物是最大的 E3 泛素连接酶家族,可介导多种特异性底物蛋白降解。两个指环家族成员 RBX1/ROC1 和 RBX2/RNF7/SAG 是多聚体 SCF 复合物泛素连接活性所必需的小分子蛋白。越来越多的证据表明 RBX 蛋白参与癌症的发病机制和发展,但以前没有使用泛癌分析来评估它们差异的研究。
我们从 TCGA 泛癌数据中研究了 RBX1/2 的表达模式及其与临床病理特征和癌症患者生存的关系。通过分子动力学模拟初步计算了 RBX1/2-CUL1 复合物的结合能。同时,我们评估了它们在包括 TISIDB 和 Timer 数据库在内的众多数据库中的免疫浸润水平。
在大多数癌症类型中观察到 RBX1/2 的高表达水平,并与分析的患者预后不良相关。然而,也存在例外情况:在 KICH 中 RBX2 的表达高于正常肾组织,并在 KICH 中起有害作用。RBX1 的表达与 KICH 的预后风险无关。此外,RBX1 和 CUL1 表达的组合比 RBX2 和 CUL1 的组合更稳定。RBX1/2 的表达在肿瘤病理分期和分级、拷贝数变异和免疫成分方面表现出其自身的特异性特征。
这些发现不仅表明 RBX1/2 的差异可能导致肿瘤进展程度不同,还表明它们可能作为癌症免疫浸润的标志物,为癌症治疗提供新的思路。